Testing PRO-203 for active systemic sclerosis
Part of Skin clinical trials.
This trial tests a new investigational medicine called PRO-203 for people with systemic sclerosis (scleroderma). It aims to see if the medicine can help control active disease that hasn't responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with systemic sclerosis (scleroderma) with active disease that hasn't improved with standard treatments.
- You have not had certain prior treatments like CAR-T, bone marrow transplant, or certain B-cell therapies in the last 6 months.
- You do not have severe lung problems or other major autoimmune diseases.
- You are willing to avoid live vaccines and have not had a recent serious infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called efgartigimod in people with systemic sclerosis (scleroderma). The goal is to see if it can safely reduce skin thickening and improve overall health. You might qualify if your skin is moderately affected and you have certain antibodies in your blood.
This study tests whether blocking a protein called TL1A can help reduce skin thickening and improve the immune system in people with systemic sclerosis (a condition where skin becomes hard and thick). Researchers will compare skin and blood samples from people with systemic sclerosis to healthy volunteers.
This trial tests a new drug, GB261, for people with systemic sclerosis (a condition that causes thickening and hardening of the skin and can affect internal organs). It aims to see if it can help when other treatments haven't worked well enough.
This trial tests a new cell therapy (UTAA91) for people with moderate-to-severe systemic sclerosis that hasn't improved with standard treatments. The goal is to see if it can help control the disease when other options have failed.
This trial tests a new treatment called CABA-201, which uses your own immune cells to target and calm the overactive immune system causing scleroderma. It aims to reduce symptoms and slow or stop the disease's progression.
This trial tests a new treatment called OL-CD19-GDT for people with systemic sclerosis or Sjögren's syndrome that hasn't responded to standard therapies. It aims to see if the treatment is safe and might help control the disease.
Hear when a new Systemic Sclerosis (SSc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.